ENXTPA:DBVBiotechs
DBV Technologies Nears Viaskin Peanut Resubmission As Funding Risks Linger
DBV Technologies plans to resubmit its Biologics License Application to the FDA for the Viaskin Peanut Patch for children after addressing earlier regulatory concerns.
The resubmission follows positive Phase 3 VITESSE trial results and a strengthened financial position.
Regulatory clearance for Viaskin Peanut could open a path to commercializing the patch in the pediatric peanut allergy market.
For investors tracking ENXTPA:DBV, the planned BLA resubmission comes at a time when the share...